Ovid Therapeutics Inc. (NASDAQ:OVID) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Ovid Therapeutics Inc. (NASDAQ:OVID – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target […]
More Stories
Stonegate Investment Group LLC Cuts Stake in American Electric Power Company, Inc. (NASDAQ:AEP)
Stonegate Investment Group LLC trimmed its position in shares of American Electric Power Company, Inc. (NASDAQ:AEP – Free Report) by...
Stonegate Investment Group LLC Boosts Stock Position in Laboratory Co. of America Holdings (NYSE:LH)
Stonegate Investment Group LLC boosted its position in shares of Laboratory Co. of America Holdings (NYSE:LH – Free Report) by...
ITT (NYSE:ITT) Price Target Raised to $167.00
ITT (NYSE:ITT – Free Report) had its price target raised by Stifel Nicolaus from $157.00 to $167.00 in a report...
Wells Fargo & Company Raises ONE Gas (NYSE:OGS) Price Target to $82.00
ONE Gas (NYSE:OGS – Free Report) had its target price hoisted by Wells Fargo & Company from $80.00 to $82.00...
Evercore ISI Raises J.B. Hunt Transport Services (NASDAQ:JBHT) Price Target to $185.00
J.B. Hunt Transport Services (NASDAQ:JBHT – Free Report) had its price target boosted by Evercore ISI from $183.00 to $185.00...
Acelyrin (NASDAQ:SLRN) Price Target Raised to $15.00
Acelyrin (NASDAQ:SLRN – Free Report) had its price objective lifted by Wells Fargo & Company from $13.00 to $15.00 in...